Short Interest in Cue Biopharma, Inc. (NASDAQ:CUE) Decreases By 6.5%

Cue Biopharma, Inc. (NASDAQ:CUE - Get Free Report) saw a significant decrease in short interest in November. As of November 30th, there was short interest totalling 1,000,000 shares, a decrease of 6.5% from the November 15th total of 1,070,000 shares. Based on an average trading volume of 762,400 shares, the short-interest ratio is currently 1.3 days.

Analysts Set New Price Targets

Separately, Stifel Nicolaus reduced their target price on shares of Cue Biopharma from $8.00 to $4.00 and set a "buy" rating for the company in a report on Tuesday, August 20th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $5.00.

Institutional Trading of Cue Biopharma

A number of hedge funds have recently bought and sold shares of the company. GSA Capital Partners LLP boosted its position in Cue Biopharma by 5.1% during the third quarter. GSA Capital Partners LLP now owns 291,663 shares of the company's stock worth $221,000 after acquiring an additional 14,104 shares during the last quarter. Geode Capital Management LLC boosted its position in Cue Biopharma by 3.3% during the third quarter. Geode Capital Management LLC now owns 508,827 shares of the company's stock worth $385,000 after acquiring an additional 16,371 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in Cue Biopharma during the second quarter worth approximately $66,000. Good Life Advisors LLC grew its stake in shares of Cue Biopharma by 23.1% during the 3rd quarter. Good Life Advisors LLC now owns 400,000 shares of the company's stock valued at $303,000 after buying an additional 75,000 shares during the period. Finally, Sigma Planning Corp grew its stake in shares of Cue Biopharma by 50.9% during the 3rd quarter. Sigma Planning Corp now owns 401,325 shares of the company's stock valued at $304,000 after buying an additional 135,295 shares during the period. Institutional investors and hedge funds own 35.04% of the company's stock.

Cue Biopharma Price Performance

Shares of CUE stock traded up $0.08 during trading hours on Monday, hitting $1.02. The company's stock had a trading volume of 249,644 shares, compared to its average volume of 454,110. The business has a fifty day moving average of $1.33 and a 200-day moving average of $1.06. The stock has a market cap of $64.62 million, a price-to-earnings ratio of -1.16 and a beta of 1.66. Cue Biopharma has a twelve month low of $0.45 and a twelve month high of $3.20. The company has a current ratio of 2.22, a quick ratio of 2.22 and a debt-to-equity ratio of 0.05.

About Cue Biopharma

Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.